ZELDIS JEROME B

Director Zeldis sold 24,000 shares (62.3% of holdings) at avg $51.50 on 2024-12-02; 30-day price up 23.4%, company unprofitable

Director Jerome B. Zeldis executed 5 separate sales totaling 24,000 shares for $1,235,897.49 on 2024-12-02, reducing his holdings from 38,500 shares to 14,500 shares (a 62.3% reduction in stake). The sales occurred at prices ranging from $50.52 to $52.42, with a blended average of $51.50, in a context where the 52-week high stands at $52.07 and current price is $49.86. The stock has appreciated 23.4% over the past 30 days and 57.8% over the past 90 days, yet PTC Therapeutics remains unprofitable with net income of $-106,654,000.00 against quarterly revenue of $196,786,000.00. Zeldis's cross-ticker historical track record shows only 50.00% win rate on 90-day outcomes post-sale, providing limited evidence of predictive selling skill. The significance lies in the substantial reduction of a director's economic stake during a period of strong price momentum in an unprofitable company, a combination that may warrant attention from investors monitoring board-level conviction and capital deployment.

Director Jerome Zeldis buys 3,636 shares of NXGL at $2.75 (Nov 20); 5 other insiders bought in past 14 days, cluster pattern amid unprofitable fundamentals.

Director Jerome Zeldis purchased 3,636 shares at $2.75 on 2024-11-20, increasing his holdings by +3.5% to 106,664 shares total. The purchase coincides with a cluster pattern: 5 other insiders also bought within the past 14 days, suggesting coordinated conviction or response to a company event. However, this must be weighed against deteriorating fundamentals—the company reported a net loss of $-693,000.00 against quarterly revenue of $2,940,000.00 and was unprofitable over its most recent full fiscal year, despite strong annual revenue growth of +99.7%. Zeldis's prior two purchases at NXGL generated mixed outcomes: the August 2024 buy showed +9.6% at 30 days and +30.8% at 90 days, but the May 2023 buy showed +13.8% at 30 days followed by -8.5% at 90 days, yielding a 50% success rate. The cluster activity and insider accumulation warrant attention given the unprofitability context.

Director ZELDIS JEROME B bought 10,000 shares of NXGL at $2.50; stock at $2.71 is -15.0% from 52-week high; cluster of 4 other insiders buying in past 14 days

ZELDIS JEROME B (Director) purchased 10,000 shares at $2.50 on 2024-08-23, increasing holdings by +10.7% to 103,028 shares. The purchase occurs amid a coordinated cluster pattern—4 other insiders also bought within the past 14 days—which may reflect shared assessment of current valuation. The stock has declined -13.7% over 30 days and -15.0% from its 52-week high of $3.19, suggesting the purchase followed a recent pullback. However, fundamentals remain challenged: the company is unprofitable with net income of $-885,000.00 on revenue of $1,440,000.00 (latest quarter) and negative full-year net income, even as annual revenue growth was +99.7%. The director's prior buy at this ticker (2023-05-26) produced -8.5% returns over 90 days, and his cross-ticker track record shows a 0.00% 90-day win rate across 1 prior buy. The concurrent insider activity warrants attention to whether this reflects informed assessment or market momentum, particularly given the company's ongoing unprofitability.